The Future of Osteoporosis: Improving Care Along the Way

Slides:

Advertisements

Similar presentations

New Dimensions and Landmark Advances in Osteoporosis Management Felicia Cosman, MD Professor of Clinical Medicine Columbia University New York, NY Osteoporosis.

Advertisements

Chapter 85 Chapter 85 Parathyroid Hormone Treatment for Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

OSTEOPOROSIS Definitions Definitions Causes Causes Investigations Investigations Treatments Treatments Case studies Case studies.

Osteoporosis Reggie Williams Elissa Kordulak Adam Moreton.

Osteoporosis Osteoporosis is defined as a loss of bone mass or bone mineral density characterized by height reduction, fractures, back/neck pain, and stooped.

Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.

Chapter 9 Skeletal health. Chapter overview Introduction Biology of bone Osteoporosis: definition, prevalence and consequences Physical activity and bone.

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

ECTS symposium 5 Anabolic treatment of osteoporosis.

1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,

1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium... 1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium...

JOCELYNE MARTINEZ Osteoporosis. OSTEOPOROSIS – CAUSES BONES TO BECOME WEAK AND BRITTLE. What is it ?

TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.

Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Advances in osteoporosis treatment John C Stevenson National Heart & Lung Institute Imperial College London Royal Brompton Hospital London, UK.

By: Dalia Munoz.  Osteoporosis is a disease in which the bones are most likely to break.  People with osteoporosis most often break bones in the hip,

Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.

UNIVERSITY of DERBY Implementing TA 161 and 204 in the real world Dr. Jonathan Bayly Visiting Fellow, University of Derby.

Food and Drug Administration Regulatory Implications of The WHI Study Eric Colman, MD Center for Drug Evaluation and Research Division of Metabolic and.

Antidepressant Medication Management Updates (CMS128) Change Review Process Meeting November 19, 2015 Jenna Williams-Bader Anne Marie Smith Stephanie Rodriguez.

Improving Evaluation and Treatment for Osteoporosis Following Distal Radial Fractures by Tamara D. Rozental, Eric C. Makhni, Charles S. Day, and Mary L.

R1 김형오 / Prof. 김덕윤 1.  Osteoporosis  Asian region is considered to be on the verge of an emerging osteoporosis epidemic  50% of the world’s osteoporotic.

J Clin Endocrinol Metab, Sep 2006, 91(9):

World Osteoporosis Day Love Your bones —Protect your future!

Stem Cells and Osteoporosis

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Chapter 61: Transplantation Osteoporosis

3Biostatistics, Pacific University, Forest Grove, Oregon, USA

Introduction to Direct-to-Consumer Genetic Testing

Goal-directed Treatment for Osteoporosis

Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.

Health Science 1 Project

9/18/2018 OSTEOPOROSIS.

Appropriate Osteoporosis Treatment by Family Physicians in Response to FRAX vs CAROC Reporting: Results From a Randomized Controlled Trial Karen A. Beattie,

ICD-10 and Clinical Documentation

Managing Women Living With HIV Infection

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Improving the Diagnosis and Treatment of Seizures in Long-term Care

Assessment of Vertebral Fractures

Bone Biology and Osteoporosis: Back to the Basics

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

HIV-Associated Weight Loss and Wasting

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Guidance for Bone Health in Parkinson's

The erlangen fitness osteoporosis prevention study: a controlled exercise trial in early postmenopausal women with low bone density—first-year results

Team-Based Perspectives on Successful Approaches in Treating Obesity

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

The Research Question RESEARCH METHOD

Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care Fred Saad, Carl Olsson, Claude C. Schulman

Deciding on Pharmacological Treatment Post Fracture

Treatment Options for Osteoporosis

Bone Biology and Osteoporosis: Back to the Basics

Navigating Treatment Options in PAH

Deciding on Pharmacological Treatment Post Fracture

Practical Challenges in Obesity: Is It Possible to Maintain Weight Loss?

Managing Age-Related Clinical Issues in Hemophilia

Bone Biology and Osteoporosis: Back to the Basics

Healthy With HIV.

Improving Adherence to Antiplatelet Therapy After an ACS Event

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Name that bone....

Interpretation The World Health Organization (WHO) Osteoporosis Guidelines (T Score vs Z score) A Z-score less than –2 indicates the diagnosis is below.

Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.

Consultant Rheumatologist Imperial College Healthcare

Subjects Randomized to Denosumab or Bisphosphonate Therapy

Case 6 Vertebral fracture

Presentation transcript:

The Future of Osteoporosis: Improving Care Along the Way

Learning Objectives

Definition of Osteoporosis

Osteoporosis Is a Serious Public Health Problem

Identified Treatment Gap NCQA HEDIS

Important Risk Factors for Fracture

Fractures and Weight

Fractures and Weight (cont)

Sclerostin Negatively Regulates Bone Formation

BA058: Lumbar Spine BMD at 24 and 48 Weeks

Zoledronic Acid + Teriparatide BMD Increases More With Combination

Summary

Abbreviations

References

References (cont)

References (cont)

References (cont)